A held protein diagnostic and therapeutic discovery business privately.

AbbVie signs special worldwide license agreement with C2N for Alzheimer’s disease therapies AbbVie today announced that it has entered into a special worldwide license agreement with C2N Diagnostics, a held protein diagnostic and therapeutic discovery business privately, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease. Tau stabilizes proteins that are in charge of the transport and framework in neuronal cells.According to Lacasse and Leo, in the scientific literature it is openly admitted that the serotonin hypothesis remains unconfirmed and that there surely is an evergrowing body of medical literature casting question on the serotonin hypothesis, which isn’t reflected in the buyer ads. For example, the broadly televised animated Zoloft commercials have dramatized a serotonin imbalance and stated, Prescription Zoloft works to correct this imbalance. Advertisements for additional SSRIs, such as for example Prozac , Paxil , and Lexapro , have made similar statements.